Lineage Cell Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

LCTX$1.04-3.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(IN THOUSANDS, EXCEPT PER SHARE DATA)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
REVENUES:
Collaboration revenues	$1,098	$2,871	$2,285	$4,992
Royalties, license and other revenues	310	354	567	619
Total revenues	1,408	3,225	2,852	5,611
OPERATING EXPENSES:
Cost of sales	44	127	142	246
Research and development	2,868	3,873	5,878	8,058
General and administrative	4,363	4,249	9,360	8,973
Total operating expenses	7,275	8,249	15,380	17,277
Loss from operations	(5,867)	(5,024)	(12,528)	(11,666)
OTHER INCOME (EXPENSES):
Interest income	463	382	925	792
Loss on marketable equity securities, net	(10)	(150)	(15)	(110)
Foreign currency transaction loss, net	(378)	(497)	(732)	(969)
Other income	19	86	19	543
Total other income (expenses)	94	(179)	197	256
LOSS BEFORE INCOME TAXES	(5,773)	(5,203)	(12,331)	(11,410)
Provision for income tax benefit	—	—	—	1,803
NET LOSS	(5,773)	(5,203)	(12,331)	(9,607)
Net (income) loss attributable to noncontrolling interest	13	(26)	29	6
NET LOSS ATTRIBUTABLE TO LINEAGE	$(5,760)	$(5,229)	$(12,302)	$(9,601)
Net loss per common share attributable to Lineage basic and diluted	$(0.03)	$(0.03)	$(0.07)	$(0.06)
Weighted-average common shares used to compute basic and diluted net loss per common share	188,813	170,592	185,861	170,361

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.